Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daré Bioscience On Prowl To Fill Gaps In Women's Sexual Health

Executive Summary

Emerging Company Profile: The company applies its mid-stage in-licensing strategy to bring in novel products for female contraception and sexual arousal disorder.

Advertisement

Related Content

Valeant Returns $1bn Female Libido Drug For Free
Cerulean Shifts From Ovarian Cancer To Contraceptives In Reverse Merger With Daré
FDA Adds New Co-Primary Endpoint For Female Sexual Desire Drugs
Sprout's Flibanserin Gets Reluctant Nod From FDA Panel, But REMS Needed
A New Dawn For Female Sex Dysfunction Drugs? FDA Meeting Cheers Sponsors

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel